| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10968257 | Vaccine | 2012 | 4 Pages |
Abstract
⺠LAIV is not recommended for children <24 months or those 24 through 59 months with asthma, recurrent wheezing, or immunocompromise. ⺠LAIV use in nonrecommended children was low compared with recommended populations. ⺠Among nonrecommended cohorts studied, use was greatest in those with recurrent wheezing. ⺠No excess in hospitalizations or ED visits within 42 days of vaccination was seen in nonrecommended populations. ⺠Few nonrecommended children were vaccinated with LAIV, precluding quantification of rare events.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Patricia Tennis, Seth L. Toback, Elizabeth B. Andrews, Lisa J. McQuay, Christopher S. Ambrose,